Pfizer - Top 15 Pharma R&D Budgets

R&D budget: $7.4B (€5.4B)
Change from 08: -2.4 percent
Income spent on R&D: 15.5%

Once the R&D leader in the industry, Pfizer ($PFE) actually slipped a little in 2009. Pfizer has been working over much of the past year to swallow up Wyeth's ambitious research group. But the combined R&D budget--Wyeth and Pfizer combined spent $11 billion on R&D in 2008--is in line for some huge cuts.

At the beginning of this year CEO Jeffrey Kindler (photo) outlined plans to chop $3 billion out of Pfizer's bloated R&D budget. By 2012, the overall R&D budget number will be downsized to $8 to $8.5 billion--along with a large number of researchers--as it falls more into line with Roche. Like many other drug developers, Pfizer has been treated to a drumbeat of criticism about a failure to develop new blockbusters to replace the big drugs that provide the bulk of its revenue. Those critics want to see more outsourcing and more partnerships and smaller in-house research empires.

This year Pfizer earned a black eye for Dimebon, which the pharma giant licensed for $225 million upfront. That drug failed a high-profile Phase III study for Alzheimer's. But that's just one of a string of clinical trial failures that has frequently put Pfizer on Wall Street's whipping post. Now Pfizer has to dramatically complete its restructuring of R&D even as it faces its biggest clinical challenge in the company's history.

One future spotlight for Pfizer: China. The pharma giant has been ambitiously expanding its research work in Asia as it sets its sights on one of the fest growing emerging markets on the planet.

Pfizer - Top 15 Pharma R&D Budgets
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.